Lee Hicks, MD
Hematology & Oncology · Lexington, KYNPI 1356342125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,012 and has fallen 60.4% since, to $797 in 2025. That places this record below the midpoint for hematology & oncology clinicians in KY, where the typical reported total is $4,619.
Across 200 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$487
- AstraZeneca$434
- Johnson & Johnson$405
- Novartis$343
- Merck$254
- E.r. Squibb & Sons, L.L.C.$208
- plus $3K from 38 others
Across 13 payments — averaging $6599.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$25K
- Beigene USA, Inc.$23K
- Seagen Inc.$17K
- Beone Medicines USA, Inc.$15K
- Pfizer$6K
What the payments were for
- Food & beverage$4,71898%
- Education$792%
- Gifts$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$154
- ONIVYDE$121
- CALQUENCE$120
- ALIYA SYSTEM$113
- IMBRUVICA$102
- OPDIVO$100
How this compares
$4,822 in reported general payments places this provider in the 50th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 102 | $1,607,443 |
| CalquenceAcalabrutinib Maleate | 72 | $999,092 |
| ErleadaApalutamide | 46 | $680,140 |
| IbrancePalbociclib | 37 | $520,171 |
| CabometyxCabozantinib S-Malate | 20 | $500,847 |
| JakafiRuxolitinib Phosphate | 30 | $498,791 |
| Abiraterone Acetate | 171 | $464,599 |
| TagrissoOsimertinib Mesylate | 25 | $423,333 |
| Lenalidomide | 31 | $390,963 |
| BrukinsaZanubrutinib | 33 | $378,871 |
| LonsurfTrifluridine/Tipiracil Hcl | 25 | $281,465 |
| PomalystPomalidomide | 14 | $274,358 |
| JaypircaPirtobrutinib | 12 | $269,890 |
| XtandiEnzalutamide | 22 | $251,912 |
| RevlimidLenalidomide | 13 | $231,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $27 | $1,607,443102 claims |
| AstraZenecaCalquence, Tagrisso | $434 | $1,422,42597 claims |
| Johnson & JohnsonErleada | $405 | $680,14046 claims |
| PfizerIbrance, Eliquis | $192 | $564,933101 claims |
| Exelixis Inc.Cabometyx | $26 | $500,84720 claims |
| Incyte CorporationJakafi | $155 | $498,79130 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $208 | $274,35814 claims |
| Astellas Pharma US IncXtandi | $51 | $251,91222 claims |
| Bristol Myers SquibbRevlimid | $71 | $231,93413 claims |
| Genentech USA, Inc.Erivedge | $125 | $184,40713 claims |
| NovartisTabrecta | $343 | $128,38812 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $16 | $46640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Lexington
- Firas BadinLexington$1.6M
- Nicola JabbourLexington$563K
- John VillanoLexington$16K
- Christopher BurkeenLexington$13K
- Jessica CroleyLexington$12K
- Roger FleischmanLexington$12K
- Ayman QasrawiLexington$9K
- Ryan WoodsLexington$6K
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.